NDAORALCAPSULE
Approved
Oct 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
9
Data completeness
6/8 — Strong
AKYNZEO (netupitant and palonosetron) by Helsinn is serotonin 3 receptor antagonists [moa]. First approved in 2014.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AKYNZEO is a fixed-dose oral combination of netupitant (NK1 receptor antagonist) and palonosetron (5-HT3 receptor antagonist) approved in 2014 for chemotherapy-induced nausea and vomiting (CINV) prevention. It works by dual antagonism of serotonin and neurokinin pathways, providing superior antiemetic coverage compared to single-agent 5-HT3 antagonists alone.
$0.005BPart D
Peak9.0 years to LOEProduct is at peak commercial stage with stable Medicare utilization; support roles focus on maintaining market position rather than growth-driven expansion.
Mechanism of Action
Serotonin 3 Receptor Antagonists
Pharmacologic Class:
Serotonin-3 Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (9)
Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)
Started Feb 2021
414 enrolled
Chemotherapy-induced Nausea and Vomiting
Observational Study on the Use of Akynzeo® in Patients Receiving HEC
Started Oct 2018
207 enrolled
Chemotherapy-Induced Nausea and Vomiting
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
Started Sep 2018
80 enrolled
Chemotherapy-induced Nausea and VomitingAdverse EventCervical Cancer
PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting
Started Aug 2017
67 enrolled
Chemotherapy-induced Nausea and Vomiting (CINV)
Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer
Started May 2017
53 enrolled
Malignant NeoplasmNauseaVomiting
Worked on AKYNZEO at Helsinn? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.